---
title: "Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294061154.md"
description: "A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions."
datetime: "2026-07-28T11:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294061154.md)
  - [en](https://longbridge.com/en/news/294061154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294061154.md)
---

# Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

- [Dyne Therapeutics director Dirk Kersten disposes of 261,460 common shares worth $6.67 million](https://longbridge.com/en/news/294254633.md)
- [Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway](https://longbridge.com/en/news/293529976.md)
- [Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock | DYN Stock News](https://longbridge.com/en/news/293412482.md)
- [Are NG, BLFS, NRIM Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/294083853.md)
- [Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday](https://longbridge.com/en/news/294069934.md)